Press Releases Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
6.56 ^USD	+0.46%		+19.49%	+47.09%

20/06	Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target	MT
20/06	TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study	14/06	AQ
Ocular Therapeutix to Host Investor Day on June 13, 2024	06/06	AQ
Ocular Therapeutix® to Host Investor Day on June 13, 2024	05/06	AQ
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/06	AQ
Ocular Therapeutix : Costs Associated with Exit/Disposal - Form 8-K	03/06	PU
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05	AQ
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05	AQ
Ocular Therapeutix: Q1 Earnings Snapshot	08/05	AQ
Ocular Therapeutix™ Reports First Quarter 2024 Results	08/05	AQ
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05	AQ
Ocular Therapeutix to Present at Two Ophthalmology Meetings, May 4-9, 2024	06/05	AQ
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences	06/05	AQ
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024	03/05	AQ
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024	01/05	AQ
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19/04	AQ
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	19/04	PU
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy	18/04	AQ
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	16/04	AQ
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders	16/04	AQ
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	15/04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Press Releases

Filters